Chappellet Becomes the Only American Winery to Be Named a Relais & Châteaux Preferred Partner
7.2.2023 17:00:00 EET | Business Wire | Press release
Napa Valley’s acclaimed Chappellet winery ( www.chappellet.com ) is excited to announce that it has been invited to become a Relais & Châteaux Preferred Partner. With this honor, Chappellet becomes the first American winery to be invited to become a Preferred Partner and joins an exclusive list of some of the world’s top wineries to be named a Relais & Châteaux Partner. Established in 1954, Relais & Châteaux is an association of more than 580 hotels and restaurants around the world operated by independent innkeepers, chefs, and owners who share a passion for excellence and a desire for authenticity in their relationships with their clientele. Preferred Partners are selected based on their shared values with Relais & Châteaux and their ability to provide unique and unforgettable experiences in their signature areas of expertise. “As a multigeneration, family-owned-and-operated winery that shares Relais & Châteaux's values and passion for excellence, we are thrilled to build on our longstanding relationship with Relais & Châteaux as a Preferred Partner,” said Cyril Chappellet, the second-generation president and chairman of Chappellet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005010/en/
View of Chappellet’s renowned estate vineyard on Pritchard Hill. (Photo: Business Wire)
Founded in 1967 by legendary vintners Donn and Molly Chappellet, Chappellet was the second post-Prohibition winery established in the Napa Valley. Inspired by the notion that “Bacchus loves the hills,” the Chappellet family settled on Pritchard Hill in the eastern mountains of Napa Valley, where they became some of the earliest pioneers of high-elevation vineyard planting. Though grapes grown above 1,000 feet represent only approximately 3% of total production in California, mountain-grown wines represent a significant portion of the most iconic and sought-after wines in America. Still independent and family-run today, Chappellet’s mountain-grown Cabernet Sauvignons from Pritchard Hill have earned global renown and are recognized as benchmarks for their region, having received multiple 100-point scores and glowing comparisons to the First Growths of Bordeaux from top wine critics.
“Since 1967, our family’s winery on Pritchard Hill has been dedicated to crafting world-class, mountain-grown Cabernet Sauvignon,” added Cyril Chappellet. “Like each Relais & Châteaux property, we strive for perfection in everything we do, from the meticulous way we organically farm our vineyard to the deep and enduring bonds we forge with our customers. Over the years, we have enjoyed remarkable relationships with many Relais & Châteaux owners and properties in North America. We look forward to building on these strong connections as we grow our presence around the globe.”
Chappellet has been partnering with a number of Relais & Châteaux properties in North America over the past decade, hosting curated weekends for their collectors at prestigious properties that include Triple Creek Ranch in Montana, The Wauwinet in Nantucket, Massachusetts, Planters Inn in Charleston, South Carolina and Auberge du Soleil in Napa Valley, California.
“I have had the pleasure of working with Chappellet at multiple Relais & Châteaux properties for the last 15 years,” said Molly Smith, the general manager of Triple Creek Ranch. “The history, familiarity, and elegance that the winery has carried through to the guests has elevated experiences and memories.”
As a Preferred Partner, Chappellet will be hosting additional special “Collectors’ Weekends” for both Relais & Châteaux members and Chappellet collectors at Relais & Châteaux properties throughout North America in 2023. The winery will also be developing new ways to engage with Relais & Châteaux members and its global association of restaurants and hotels, including vintner dinners, tasting events, wine education experiences, and the expansion of Chappellet’s “Collectors’ Weekends” into Europe and Asia.
In commenting on Chappellet’s new status as a Preferred Partner, David Fink, the proprietor of Relais & Châteaux property L'Auberge Carmel, said, “More than half a century ago, Donn Chappellet left his corporate life in Los Angeles to find one of the most idyllic places to raise a family and become a wine grower. Today, the Chappellet family carries Donn's vision forward and has created some of the most special wines made in California.”
About Chappellet
In 1967, on the advice of legendary winemaker André Tchelistcheff, the Chappellet family settled on the steep slopes of Pritchard Hill© and founded Chappellet, becoming just the second post-Prohibition winery in Napa Valley. As pioneers of high-elevation vineyard planting, Chappellet has earned acclaim for crafting benchmark wines with an emphasis on mountain-grown Cabernet Sauvignons, while establishing Pritchard Hill as one of the world’s great wine regions.
About Relais & Châteaux - A Movement with Meaning
Relais & Châteaux, established in 1954, is an association of 580 unique hotels and restaurants throughout the world, owned and operated by independent entrepreneurs – most often families – who are passionate about their craft and deeply committed to forging warm, lasting relationships with their guests. Relais & Châteaux members protect and promote the wealth and diversity of the world’s culinary and hospitality traditions, to ensure they continue to thrive. They are equally dedicated to preserving local heritage and the environment, as articulated in the association’s Vision presented to UNESCO in November 2014. For more information, visit www.relaischateaux.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005010/en/
Contact information
Sonia Ginsburg
Sonia@jam-pr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 14:33:00 EEST | Press release
The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simultaneously building a robust pipeline of next-generation programs in AI-guided neuromodulation and min
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 14:24:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: "While the median age of diagnosis for CLL is 70 and the average age of treatment initiation is 75, many pivotal trials still underrepresent the patients that physicians most often see in practice. These data show that the durable benefit of
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 14:00:00 EEST | Press release
Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction. GreensLedge Capital Markets advised the seller. About Clearlake Clearlake Capital is a leading global alternative a
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 14:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrated statistical superiority over deucravacitinib for all key secondary endpoints, including PASI 90 response and Static Physician's Global Assessment (sPGA) 0 at week 16. Zasocitinib was generally well tolerated with a consistent safety and tolerability profile and no new safety signals identified. Perspectives on head-to-head zasocitinib study “In this head-to-head study, zasocitinib clearly demonstrated
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 13:30:00 EEST | Press release
L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reliability, operational efficiency and sustainability performance. The partnership brings together LTTS’ expertise in forward looking technologies and extensive experience ac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
